BeOne Medicines AG
ONC
$316.99
-$5.38-1.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.06% | 40.42% | 41.56% | 48.64% | 73.87% |
| Total Other Revenue | 121.96% | 111.86% | -- | -- | -- |
| Total Revenue | 32.84% | 41.00% | 41.56% | 48.64% | 75.39% |
| Cost of Revenue | -11.30% | 15.28% | 19.17% | 32.07% | 43.46% |
| Gross Profit | 40.16% | 46.28% | 45.47% | 51.95% | 82.12% |
| SG&A Expenses | 10.03% | 16.21% | 21.23% | 7.45% | 24.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.77% | 11.35% | 18.44% | 9.20% | 17.84% |
| Operating Income | 332.97% | 235.63% | 182.01% | 104.25% | 79.18% |
| Income Before Tax | 274.86% | 249.70% | 193.99% | 108.59% | 73.37% |
| Income Tax Expenses | 24.36% | -3.14% | -63.90% | 154.14% | 365.00% |
| Earnings from Continuing Operations | 143.79% | 202.88% | 178.34% | 100.51% | 54.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 143.79% | 202.88% | 178.34% | 100.51% | 54.63% |
| EBIT | 332.97% | 235.63% | 182.01% | 104.25% | 79.18% |
| EBITDA | 822.86% | 496.46% | 241.18% | 118.01% | 91.54% |
| EPS Basic | 142.02% | 198.86% | 175.71% | 100.49% | 55.57% |
| Normalized Basic EPS | 331.38% | 256.39% | 194.24% | 109.14% | 88.74% |
| EPS Diluted | 136.29% | 188.89% | 166.67% | 100.46% | 55.16% |
| Normalized Diluted EPS | 322.05% | 250.51% | 190.69% | 108.79% | 88.74% |
| Average Basic Shares Outstanding | 4.21% | 4.07% | 3.46% | 2.55% | 2.10% |
| Average Diluted Shares Outstanding | 8.58% | 8.13% | 7.51% | 6.62% | 2.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |